NCT00090987 - Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Sarcoma

Interventions

DRUG

imatinib mesylate

400 mg orally once a day for up to 6 months.

Trial Locations (15)

10021

Memorial Sloan - Kettering Cancer Center, New York

10461

Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx

19106

Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia

33136

University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami

63110

Siteman Cancer Center at Barnes-Jewish Hospital, St Louis

92262

Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs

94115

UCSF Comprehensive Cancer Center, San Francisco

98101

Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle

92093-0658

Moores UCSD Cancer Center, La Jolla

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

02215

Beth Israel Deaconess Medical Center, Boston

44106-5065

Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

lead

AIDS Malignancy Consortium

NETWORK